Targeting the oncogene LSF with either the small molecule inhibitor FQI1 or siRNA causes mitotic delays with unaligned chromosomes, resulting in cell death or senescence

The oncogene LSF (encoded by TFCP2) has been proposed as a novel therapeutic target for multiple cancers. LSF overexpression in patient tumors correlates with poor prognosis in particular for both hepatocellular ...

Source: BMC Cancer - July 6, 2020 Category: Cancer & Oncology Authors: Jennifer L. S. Willoughby, Kelly George, Mark P. Roberto, Hang Gyeong Chin, Patrick Stoiber, Hyunjin Shin, Chandra Sekhar Pedamallu, Scott E. Schaus, Kevin Fitzgerald, Jagesh Shah and Ulla Hansen Tags: Research article Source Type: research